Other Non-Current Liabilities
Bristol-Myers Squibb Other Non-Current Liabilities decreased by 3.8% to $4.85B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $4.48B to $4.85B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows a downward trend with a -8.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.50B | $7.52B | $7.33B | $7.31B | $6.64B | $6.69B | $6.59B | $6.66B | $5.90B | $6.20B | $6.42B | $6.73B | $4.99B | $4.73B | $4.47B | $4.48B | $4.94B | $5.46B | $5.04B | $4.85B |
| QoQ Change | — | +0.2% | -2.4% | -0.3% | -9.2% | +0.7% | -1.4% | +1.1% | -11.4% | +5.1% | +3.5% | +4.8% | -25.8% | -5.3% | -5.5% | +0.2% | +10.4% | +10.5% | -7.6% | -3.8% |
| YoY Change | — | — | — | — | -11.4% | -11.1% | -10.1% | -8.8% | -11.1% | -7.2% | -2.6% | +1.0% | -15.4% | -23.8% | -30.4% | -33.5% | -1.0% | +15.5% | +12.8% | +8.4% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's other non-current liabilities?
- Bristol-Myers Squibb (BMY) reported other non-current liabilities of $4.85B in Q1 2026.
- How has Bristol-Myers Squibb's other non-current liabilities changed year-over-year?
- Bristol-Myers Squibb's other non-current liabilities increased by 8.4% year-over-year, from $4.48B to $4.85B.
- What is the long-term trend for Bristol-Myers Squibb's other non-current liabilities?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's other non-current liabilities has grown at a -8.3% compound annual growth rate (CAGR), from $7.78B to $5.04B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.